Message from the President:

Hello! My name is Heather Napolitano.  When I began losing my vision, my husband and I were scared and searching everywhere for answers.  The sense of community and support we felt upon finding the FFB was indescribable.  They lifted our hopes and instilled a fight within us to find a cure.

Foundation Fighting Blindness Partners with Vision Medicines to Develop Stargardt Disease Therapy

The Foundation Fighting Blindness and the biopharmaceutical company Vision Medicines are partnering to develop a drug known as VM200 for preserving vision in people with Stargardt disease, the leading cause of inherited juvenile macular degeneration. The Foundation is committing $7.5 million to co-fund VM200 development. Vision Medicines plans to launch a human study of the emerging therapy in 2016.

Foundation Fighting Blindness Applauds Phase 3 Study Results for Investigational Gene Therapy Treatment

Spark Therapeutics today announced positive top-line results from a Phase 3 pivotal trial of SPK-RPE65, an investigational gene therapy product for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). This research was funded in part by the Foundation Fighting Blindness, the world’s largest private funder of early, translational and clinical-stage research for blinding retinal diseases.